**References**

1. Afageh BH, Wang Z, Mongkhon P, et al (2019) Safety and tolerability of antipsychotic medication in individuals with autism spectrum disorder: A systematic review and meta-analysis. *Pediatric Drugs*, **21**: 153-67.
2. Aman MG, Burrow WH, Wolford PL (1995) The aberrant behavior checklist community: factor validity and effect of subject variables for adults in group homes. *American Journal on Mental Retardation*, **100**: 283-92.
3. Aman MG, Mcdougle CJ, Scahill L, et al. (2009) Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, **48**:1143-54.
4. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. (2002) The Risperidone Disruptive Behavior Study Group: Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: A double-blind, placebo-controlled study. *American Journal of Psychiatry*, **159**, 1337-46.
5. American Psychiatric Association (2013) *Diagnostic and statistical manual of mental disorders: DSM-5.* Washington, D.C. USA: American Psychiatric Publishing.
6. Bachmann CJ, Manthey T, Kamp-Becker I, et al (2013) Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. *Research in Developmental Disabilities*, **34**: 2551-63.
7. Baribeaua D, Vorstmana J, Anagnostou E (2022) Novel treatments in autism spectrum disorder. *Current Opinion in Psychiatry*, **35**: 101-10.
8. Bertelli MO, Azeem MW, Underwood L, et al (2022) Autism Spectrum Disorder. In *Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder* (eds MO Bertelli, S Deb, K Munir, A Hassiotis, L Salvador-Carulla): 369-455. Springer Nature.
9. Bertelli MO, Piva Merli M, Bradley E, et al (2015) The diagnostic boundary between autism spectrum disorder, intellectual developmental disorder and schizophrenia spectrum disorders. *Advances in Mental Health in Intellectual Disabilities*, **9**: 243-64.
10. Biswas A, Baldwin D, Hiremath A, et al (2021) *Stopping the overmedication of people with intellectual disability, autism or both (STOMP) and supporting treatment and appropriate medication in paediatrics (STAMP).* Royal College of Psychiatrists, London, UK (PS 05/21) (<https://pearl.plymouth.ac.uk/bitstream/handle/10026.1/17746/position-statement-ps0521-stomp-stamp.pdf?sequence=1> [cited 10 May2022])
11. Branford D, Gerrard D, Saleem N, et al (2019) Stopping over-medication of people with intellectual disability, Autism or both (STOMP) in England part 1-history and background of STOMP. *Advances in Mental Health and Intellectual Disabilities*, **13**: 31-40.
12. Branford D, Shankar R (2022) Antidepressant prescribing for adult people with an intellectual disability living in England. *British Journal of Psychiatry*, 1-6. Available from: <https://doi.org/10.1192/bjp.2022.34>

1. Bruinsma E, van den Hoofdakker BJ, Groenman AP, et al (2020) Non-pharmacological interventions for challenging behaviours of adults with intellectual disabilities: A meta-analysis. *Journal of Intellectual Disability Research,* **64**: 561-78.
2. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT. (2001) A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with sub average cognitive abilities. *Journal of Clinical Psychiatry*, **62**: 239-48.
3. Cerovecki A, Musil R, Klimke A, et al (2013) Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. *CNS Drugs,* **27**: 545-72.
4. Chouinard G, Chouinard V-A (2008) Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. *Psychotherapy and Psychosomatics*, **77**: 69–77. Available from: <https://doi.org/10.1159/000112883>
5. Citrome L (2017) Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder. *Journal of Clinical Psychopharmacology*, **37**: 138–47.
6. Coccaro EF (2020) The Overt Aggression Scale Modified (OAS-M) for clinical trials targeting impulsive aggression and intermittent explosive disorder: Validity, reliability, and correlates. *Journal of Psychiatric Research*, **124**: 50-7.
7. Croonenberghs J, Fegert JM, Findling RL, et al (2005) Risperidone in children with disruptive behaviour disorders and sub-average intelligence: a 1 year open-label study of 504 patients. *Journal of the American Academy of Child and Adolescent Psychiatry*, **44**: 64-72.
8. Coury DL, Anagnostou E, Manning-Courtney P, et al (2012) Use of psychotropic medication in children and adolescents with autism spectrum disorders. *Pediatrics*, **130**(suppl 2): s69-76.
9. D'Alò GL, Crescenzo FD, Amato L, et al. on behalf of the ISACA Guideline Working group (2021) Impact of antipsychotics in children in children and adolescents with autism spectrum disorder: A systematic review and meta-analysis. *Health and Quality of Life Outcomes*, **19**: 33. Available from: <https://doi.org/10.1186/s12955-021-01669-0>
10. Deb S (2016) Psychopharmacology. In *Handbook of Evidence-Based Practices in Intellectual and Developmental Disabilities,* *Evidence-Based Practices in Behavioral Health* (ed NN Singh): 347-381. Springer International Publishing.
11. Deb S, Bertelli MO, Rossi M (2022b) Psychopharmacology. In *Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder* (eds MO Bertelli, S Deb, K Munir, A Hassiotis, L Salvador-Carulla): 247-280. Springer Nature.
12. Deb S, Bethea T, Havercamp S, et al (2016) Disruptive, impulse-control, and conduct disorders. In *Diagnostic manual - Intellectual disability: A textbook of diagnosis of mental disorders in persons with intellectual disability* (eds R Fletcher, J Barnhill, S-A Cooper): 521-60. NADD Press.
13. Deb S, Chaplin R, Sohanpal S, et al (2008) The effectiveness of mood stabilisers and antiepileptic medication for the management of behaviour problems in adults with intellectual disability: a systematic review. *Journal of Intellectual Disability Research*, **52**: 107-13.
14. Deb S, Farmah BK, Arshad E, et al (2014) The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder: a systematic review. *Research in Developmental Disabilities*, **35**: 711-25. Available from: <https://doi.org/10.1016/j.ridd.2013.12.004>.
15. Deb S, Fraser WI (1994) The use of psychotropic medication in people with learning disability: towards rational prescribing. *Human Psychopharmacology*, **9**: 259-72.
16. Deb S, Kwok H, Bertelli M, et al (2009) International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. *World Psychiatry,* **8**: 181-6.
17. Deb S, Limbu B, Nancarrow T, Gerrard D, Shankar R. (2022c) The UK psychiatrists’ experience of rationalising antipsychotics in adults with intellectual disabilities: a qualitative data analysis of free-text questionnaire responses. *BMC Psychiatry* (under review).
18. Deb S, Limbu B, Unwin G, et al (2021a) Short-term Psycho-Education for Caregivers To Reduce OverMedication of people with intellectual disabilities (SPECTROM): development and field testing. *International Journal of Environmental Research and Public Health*, **18**: 13161. Available from: <https://doi.org/10.3390/ijerph182413161>
19. Deb S, Nancarrow T, Limbu B, et al (2020) UK Psychiatrists’ experience of withdrawal of antipsychotics prescribed for behaviours that challenge in adults with intellectual disabilities and/or autism. *British Journal of Psychiatry Open*, **6**: e112, 1-7. Available from: <https://doi.org/10.1192/bjo.2020.9>
20. Deb S, Perera B, Bertelli MO (2022e) Attention Deficit Hyperactivity Disorder. In *Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder* (eds MO Bertelli, S Deb, K Munir, A Hassiotis, L Salvador-Carulla): 457-482. Springer Nature, Cham, Switzerland.
21. Deb S, Perera B, Krysta K, Ozer M, Bertelli M, Novell R, Wieland J, Sappok T. (2022) The European guideline on the assessment and diagnosis of psychiatric disorders in adults with intellectual disabilities. *European Journal of Psychiatry,* **36**: 11-25.
22. Deb S, Roy M, Lee R, Majid M, et al (2021b) Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis. *British Journal of Psychiatry Open,* **7**, e179, 1-15. Available from: https://doi.org/10.1192/bjo.2021.1003.
23. Deb S, Roy M, Limbu B, Bertelli B (2022d) Anti-anxiety medications and novel treatments for autism. In *Handbook of Autism and Pervasive Developmental Disorders* (eds JL Matson, P Sturmey). Springer Nature Switzerland AG (in press).
24. Deb S, Unwin G, Cooper S-A, Rojahn J (2022a) Problem behaviours. In *Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder* (eds MO Bertelli, S Deb, K Munir, A Hassiotis, L Salvador-Carulla): 145-186. Springer Nature.
25. Deb S, Unwin G, Deb T (2015) Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. *Journal of Intellectual Disability Research*, **59**: 11-25.
26. de Kuijper G, Hoekstra P, Visser F, et al (2010) Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescription. *Journal of Intellectual Disability Research*, **54**(7): 659-67.
27. DeVane CL, Charles JM, Abramson RK, et al. (2019) Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, **39**:626-35.
28. Findling RL, Aman MG, Eerdekens M, et al. (2004) Risperidone Disruptive Behavior Study Group. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. *American Journal of Psychiatry*, **161**(4):677-84.
29. Findling RL, Mankoski R, Timko K, et al. (2014) A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. *The Journal of clinical psychiatry*, **75**(1):16656.
30. Frighi V, Stephenson MT, Morovat A, et al (2011) Safety of antipsychotics in people with intellectual disability. *British Journal of Psychiatry*, **199**: 289-95.
31. Ghanizadeh A, Sahraeizadeh A, Berk M. (2014) A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. *Child Psychiatry & Human Development*, **45**(2):185-92.
32. Glover G, Williams R, Branford D, et al (2015) Prescribing of psychotropic drugs to people with learning disabilities and/or autism by general practitioners in England. *Public Health England*, UK.
33. Gore NJ, Sapiets SJ, Denne LD, Hastings RP, Toogood S, MacDonald A., et al. Positive Behavioural Support in the UK: A state of the nation report. International J Positive Behavioural Support. 2022;12(Supplement 1):4-39.
34. Hellings JA, Zarcone JR, Reese RM, et al (2006) A crossover study of risperidone in children, adolescents and adults with mental retardation. *Journal of Autism and Developmental Disorders*, **36**: 401-11. Available from: <https://doi.org/10.1007/s10803-006-0078-1>
35. Henderson A, Kinnear D, Fleming M, et al (2021) Antipsychotic and antidepressant prescribing for 704 297 children and young people with and without intellectual disabilities: record linkage study. *British Journal of Psychiatry*, **218**: 58–62.
36. Henderson A, Mcskimming P, Kinnear D, et al (2020) Changes over a decade in psychotropic prescribing for people with intellectual disabilities: prospective cohort study. *British Medical Journal Open*, 10: e036862. doi:10.1136/ bmjopen-2020-036862
37. Higgins JPT, SavovićJ, Page MJ, et al (2020) Assessing risk of bias in a randomized trial. In *Cochrane Handbook for Systematic Reviews of Interventions Version 6.1* (Updated September 2020) (eds JPT Higgins, J Thomas, J Chandler, M Cumpston, T Li, MJ Page, VA Welch): 205–28. John Wiley & Sons.
38. Hollander E, Chaplin W, Soorya L, et al (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. *Neuropsychopharmacology*, **35**: 990-8.
39. Hollander E, Soorya L, Wasserman S, et al (2006) Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. *International Journal of Neuropsychopharmacology*, **9**: 209-13.
40. Hollander E, Wasserman S, Swanson EN, et al. (2006) A Double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. *Journal of Child & Adolescent Psychopharmacology*, **16**: 541-8.
41. Ichikawa H, Mikami K, Okada T, et al. (2017) Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: A randomized, double-blind, placebo-controlled study. *Child Psychiatry & Human Development*, **48**(5):796-806.
42. Jadad AR, Moore RA, Carroll D, et al (1996) Assessing the quality of reports of randomised clinical trials: is blinding necessary? *Controlled Clinical Trials*, **17**: 1-12.
43. Jahromi LB, Kasari CL, McCracken JT, et al (2009) Positive effect of methylphenidate on social communication and self-regulation in children with pervasive developmental disorder and hyperactivity. *Journal of Autism and Developmental Disabilities*, **39**: 395-404.
44. NCT01624675, Janssen Pharmaceutical K.K. (2015) *A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder.* ClinicalTrials.gov NCT01624675 ([https://clinicaltrials.gov/ct2/show/NCT01624675 cited 10 June 2022](https://clinicaltrials.gov/ct2/show/NCT01624675%20cited%2010%20June%202022)]).
45. Ji NY, Findling RL (2015) An update on pharmacotherapy for autism spectrum disorder in children and adolescents. *Current Opinion in Psychiatry*, **28**: 91-101.
46. Ji NY, Findling RL (2016) Pharmacotherapy for mental health problems in people with intellectual disability. *Current Opinion in Psychiatry*, **29**: 103-25.
47. Kalachnik JE, Hanzel TE, Sevenich R, Harder SR (2002) Benzodiazepine behavioral side effects: Review and implications for individuals with mental retardation. *American Journal on Mental Retardation*, **107**: 376–410.
48. Kent JM, Kushner S, Ning X, et al. (2013) Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. *Journal of autism and developmental disorders*, 43: 1773-83.
49. Kouhbanani SS, Khosrorad R, Zarenezhad S, Arabi SM. (2021) Comparing the Effect of Risperidone, Virtual Reality and Risperidone on Social Skills, and Behavioral Problems in Children with Autism: A Follow-up Randomized Clinical Trial. *Archives of Iranian Medicine*, **24**(7): 534-41.
50. Lai M-C, Kassee C, Besney R, et al (2019) Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. *Lancet Psychiatry*, **6**: 819–29.
51. Limbu B, Deb S, Roy M, et al (2022) Randomised controlled trials of mood stabilisers for people with autism spectrum disorder: a systematic review and a meta-analysis. *British Journal of Psychiatry Open*, **8**, e52, 1-12. Available from: <https://doi.org/10.1192/bjo.2022.18>
52. Loebel A, Brams M, Goldman RS, et al. (2016) Lurasidone for the treatment of irritability associated with autistic disorder. *Journal of autism and developmental disorders*, **46**: 1153-63.
53. Lord C, Rutter M, DiLavore PC, Risi S (1999) Autism diagnostic observation schedule-WPS (ADOS-WPS). *Western Psychological Services*.
54. Luby J, Mrakotsky C, Stalets MM, et al (2006) Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. *Journal of Child & Adolescent Psychopharmacology*, **16**: 575-87.
55. Lugo-Marína J, Magán-Magantob M, Rivero-Santanac A, et al (2019) Prevalence of psychiatric disorders in adults with autism spectrum disorder: A systematic review and meta-analysis. *Research in Autism Spectrum Disorders*, **59**: 22-33.
56. Mandell DS, Morales KH, Marcus SC, et al (2008) Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. *Pediatrics*, **121**, e441–e448.
57. Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H. and Aman, M. G. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, **48**(11): 1110-19.
58. Marcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., *et al.* (2011). Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: a 52-week open-label study. *Journal of Child and Adolescent Psychopharmacology*, **21**(3): 229-36.
59. Marston L, Nazareth I, Petersen I, et al (2014) Prescribing of antipsychotics in UK primary care: a cohort study. *British Medical Journal Open*, **4**: e006135.
60. McCracken JT, McGough J, Shah B, et al (2002) Risperidone in children with autism and serious behavioral problems. *New England journal of medicine*, **347**: 314-21.
61. McDonald A (2019) Positive Behaviour Support. In *Understanding and responding to behaviour that challenges in Intellectual Disabilities: A Handbook for those who provide support* (eds P Baker, T Osgood): 31-40. Pavilion Press, Tizard University of Kent and Challenging Behaviour Foundation, London UK.
62. NCT00198107, McDougle CJ. (2019) *Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism*. ClinicalTrials.gov NCT00198107 (<https://www.clinicaltrials.gov/ct2/show/NCT00198107> [cited 10 June 2022]).
63. McDougle CJ, Holmes JP, Carlson DC, et al. (1998) A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. *Archives of General Psychiatry*, **55**: 633-41.
64. McNamara R, Randell E, Gillespie D, et al (2017) A pilot randomised controlled trial of community-led ANtipsychotic Drug REduction for Adults with Learning Disabilities. *Health Technology Assessment*, **21**. Available from: https://doi.org/10.3310/hta21470
65. Mehta H, Glover G (2019) Psychotropic drugs and people with learning disabilities or autism. *Public Health England*.
66. Miral S, Gencer O, Inal-Emiroglu FN, et al. (2008) Risperidone versus haloperidol in children and adolescents with AD. *European child & adolescent psychiatry*, **17**(1): 1-8.
67. Mulhall P, Taggart L, Coates V, et al (2018) A systematic review of the methodological and practical challenges of undertaking randomised-controlled trials with cognitive disability populations *Social Science & Medicine*, **200**: 114-28.
68. Murray ML, Hsia Y, Glaser K, et al. (2014) Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. *Psychopharmacology,* **231**: 1011-21.
69. Nagaraj R, Singhi P, Malhi P. (2006) Risperidone in children with autism: randomized, placebo-controlled, double-blind study. *Journal of Child Neurology*, **21**:450-5.
70. National Institute of Mental Health (1985) CGI (clinical global impression scale)-NIMH. *Psychopharmacology Bulletin*, **21**: 839-44.
71. National Institute for Health and Care Excellence (NICE) (2015) Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. *NICE Guideline* 11, Methods, evidence and recommendations.
72. Nikvarz N, Alaghband-Rad J, Tehrani-Doost M, et al. (2016) Comparing efficacy and side effects of memantine vs. risperidone in the treatment of autistic disorder. *Pharmacopsychiatry*, **50**(01): 19-25.
73. Oliver-Africano PC, Dickens S, Ahmed Z, et al (2010) Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities. *Journal of Intellectual Disability Research*, **54**: 17-25.
74. Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., *et al.* (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. *Pediatrics*, **124**(6): 1533-40.
75. Pearson DA, Santos C, Aman MG, et al (2013) Effects of extended release methylphenidate treatment on ratings of Attention-Deficit/ Hyperactivity (ADHD) and associated behavior in children with Autism Spectrum disorders and ADHD symptoms. *Journal of Child and Adolescent Psychopharmacology*, **23**: 337-51.
76. Planès S, Villier C, Mallaret M (2016) The nocebo effect of drugs. *Pharmacology Research & Perspective*, **4**: e00208.
77. Ramerman L, de Kuijper G, Scheers T, et al (2019) Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study. *Journal of Intellectual Disability Research*, **63**: 418–28. Available from: https://doi.org/10.1111/jir.12584
78. Ramerman L, Hoekstra PJ, de Kuijper G (2018a) Health-related quality of life in people with intellectual disability who use long-term antipsychotic drugs for challenging behaviour. *Research in Developmental Disabilities*, **75**: 49-58.
79. Ramerman L, Hoekstra PJ, de Kuijper G (2018b) Changes in Health-Related Quality of Life in people with intellectual disabilities who discontinue long-term used antipsychotic drugs for challenging behaviors. *Journal of Clinical Pharmacology*, **59**: 280-7.
80. Ratey JJ, Gutheil CM (1991) The measurement of aggressive behaviour: reflections on the use of the Overt Aggression Scale and the Modified Overt Aggression Scale. *Journal of Neuropsychiatry*, **3**: 557-60.
81. Research Unit on Pediatric Psychopharmacology (RUPP) Autism Network (2005) Randomized, controlled, crossover trial of methylphenidate in Pervasive Developmental Disorders with hyperactivity. *Archives of General Psychiatry*, **62**: 1266-74.
82. RUPP (Research Units on Pediatric Psychopharmacology) Autism Network (2002). Risperidone in children with autism and serious behavioural problems. *The New England Journal of Medicine*, **347**: 314-21.
83. RUPP (Research Units on Pediatric Psychopharmacology) Autism Network (2005). Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. *American Journal of Psychiatry*, **162**: 1361-9.
84. Reid AH, Naylor GJ, Kay DSG (1981) A double-blind, placebo-controlled, crossover trial of carbamazepine in overactive severely mentally handicapped patients. *Psychological Medicine,* **11**: 109-13.
85. Reiss S, Sysko J (1993) Diagnostic overshadowing and professional experience with mentally retarded persons. *American Journal of Mental Deficiency*, **47**: 415−21.
86. Roy A, Roy M, Deb S, Unwin G, Roy A (2015a) Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children? a systematic review. *Journal of Intellectual Disability Research*, **59**: 293-306.
87. Roy A, Roy M, Deb S, Unwin G, Roy A (2015b) Are opioid antagonists effective in adults with intellectual disability? a systematic review. *Journal of Intellectual Disability Research*, **59**: 55-67.
88. Scahill L, McDougle CJ, Williams SK, et al (2006) Children’s Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. *Journal of the American Academy of Child & Adolescent Psychiatry*, **45**: 1114–23.
89. Scheifes A, Stolker JJ, Egberts ACG, et al (2011) Representation of people with intellectual disabilities in randomized controlled trials of antipsychotic treatment for behavioural problems. *Journal of Intellectual Disability Research*, **55**: 650-64.
90. Shankar R, Wilcock M, Deb S, et al (2019) A structured programme to withdraw antipsychotics among adults with intellectual disabilities: The Cornwall experience. *Journal of Applied Research in Intellectual Disability*, **32**: 1389-400.
91. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. *Pediatrics*, **114**: e634-41.
92. Sheehan R, Hassiotis A (2017) Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review. *Lancet Psychiatry*, **4**: 238-56.
93. Sheehan R, Hassiotis A, Walters K, et al (2015) Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population-based cohort study. *British Medical Journal*, **351**: h4326.
94. Simonoff E, Pickles A, Charman T, et al (2008) Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. *Journal of the American Academy of Child & Adolescent Psychiatry*, **47**: 921-9.
95. Simonoff E, Taylor E, Baird G, et al. (2013) Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. *Journal of Child Psychology and Psychiatry*, **54**: 527-35.
96. Snyder R, Turgay A, Aman M, Binder C, Fisman S., Allan C. and the Risperidone Conduct Study Group (2002) Effects of risperidone on conduct and disruptive behaviour disorders in children with sub average IQs. *Journal of the American Academy of Child & Adolescent Psychiatry*, **41**: 1026-36.
97. Sohanpal SK, Deb S, Thomas C, et al (2007) The effectiveness of antidepressant medication in the management of behaviour problems in adults with intellectual disabilities: a systematic review. *Journal of Intellectual Disability Research*, **51**: 750-65.
98. Tarrant N, Roy M, Deb S, et al (2018) The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities: a systematic review. *Research in Developmental Disabilities*, **83**: 217-232.
99. Tassé MJ, Aman MG, Hammer D, Rojahn J (1996) The Nisonger Child Behavior Rating Form: age and gender effect and norms. *Research in Developmental Disabilities*, **17**: 59-75.
100. Troost PW, Lahuis BE, Steenhuis MP, et al. (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. *Journal of the American Academy of Child & Adolescent Psychiatry*, **44,** 1137-44.
101. Turgay, A., Binder, C., Snyder, R. and Fisman, S. (2002). Long-term safety and efficacy of risperidone for the treatment of disruptive behaviour disorders in children with sub average IQs. *Pediatrics*, **110**: e34. Pp. 1-12.
102. Tyrer P, Oliver-Africano PC, Ahmed Z, Bouras N, Cooray S, Deb S, et al. (2008) Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. *Lancet*, **371**: 57-63.
103. Gagiano, C., Read, S., Thorpe, L., Eerdekens, M. and Van Hove, I. (2005). Short- and long-term efficacy and safety of risperidone in adults with disruptive behaviour disorders. *Psychopharmacology*, **179**: 629-36.
104. Unwin G, Deb S (2008a) A multi-centre audit of practice of prescribing psychotropic medication among adults with intellectual disabilities. *British Journal of Learning Disability,* 36: 140-3.
105. Unwin G, Deb S (2008b) Use of medication for the management of behaviour problems among adults with intellectual disabilities: a clinicians’ consensus survey. *American Journal on Mental Retardation*, **113**: 19-31.
106. Unwin GL, Deb S (2011) Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: a systematic review. *Research in Developmental Disabilities,* **32**: 2121-33.
107. van Bellinghen, M. and De Troch, C. (2001). Risperidone in the treatment of behavioural disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. *Journal of Child and Adolescent Psychopharmacology*, **11**: 5-13.
108. van Den Borre R, Vermote R, Buttiens M, Thiry P, Dierick G, Geutiens J, *et al.* (1993) Risperidone as an add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. *Acta Psychiatrica Scandinavica*, **87**: 167-71.
109. Wang M, Jiang L, Tang X (2017) Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder. *Neuropsychiatric Disorders and Treatment,* **13**: 2321.